Can I Take Vitamin B12 with Zetia (Ezetimibe)?

How Ezetimibe Works, and Why B12 Is Unaffected

Ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestinal epithelium, blocking sterol absorption. In the SHARP trial (N=9,270), ezetimibe plus simvastatin reduced LDL-C by approximately 17 mg/dL compared to placebo and cut major vascular events by 17% (relative risk 0.83, 95% CI 0.74 to 0.94, P<0.001). That mechanism targets a lipid transporter. It does not alter bile acid reabsorption in the ileum, gastric acid secretion, or intrinsic-factor production.

How Vitamin B12 Is Absorbed

Vitamin B12 absorption follows a completely separate physiological route. Dietary B12 binds to intrinsic factor secreted by gastric parietal cells, and the B12-intrinsic factor complex is absorbed at specific receptors in the terminal ileum. This pathway depends on gastric acid, intrinsic factor, and ileal receptor integrity, none of which ezetimibe affects.

NPC1L1 Versus Intrinsic Factor Receptors

The NPC1L1 transporter is expressed primarily in the proximal jejunum for cholesterol absorption. The cubilin-amnionless receptor complex for B12 is expressed in the terminal ileum. These two transporter systems do not overlap anatomically or molecularly. Structural studies confirm NPC1L1 has no binding affinity for cobalamin compounds.

What the FDA Label Says

The FDA-approved prescribing information for ezetimibe lists no interaction with vitamins or micronutrients. The full Zetia prescribing information documents interactions with cyclosporine, fenofibrate, cholestyramine, and coumarin anticoagulants, vitamin B12 is absent from the interaction table.

Pharmacokinetic Profile of Ezetimibe: No B12 Collision Points

Understanding why there is no interaction requires a brief look at ezetimibe's pharmacokinetics. Ezetimibe is rapidly absorbed after oral dosing, glucuronidated in the intestinal wall and liver to its active form (ezetimibe-glucuronide), and undergoes enterohepatic recycling. Peak plasma concentration (Tmax) occurs at 4 to 12 hours post-dose; mean half-life is approximately 22 hours, with 78% of a dose recovered in feces and 11% in urine.

Protein Binding and Distribution

Ezetimibe and its glucuronide are both highly protein-bound (greater than 90%). Vitamin B12, by contrast, circulates bound to transcobalamin II and haptocorrin. These are entirely different carrier proteins. No displacement interaction has been reported or mechanistically predicted.

Hepatic Metabolism

Ezetimibe is metabolized primarily by UGT1A3 glucuronyl transferase, not by cytochrome P450 enzymes. Because ezetimibe bypasses CYP450 pathways, it has a low interaction potential with most drugs and supplements. Vitamin B12 requires no hepatic enzyme metabolism for activation; its conversion to methylcobalamin and adenosylcobalamin occurs inside mitochondria via reductase enzymes unrelated to UGT1A3.

Gastrointestinal Transit Effects

Ezetimibe does not meaningfully alter gastrointestinal motility, gastric emptying time, or intestinal pH. A pharmacology review published in the Journal of Lipid Research confirmed that ezetimibe's tissue selectivity is confined to the sterol absorption pathway, with no documented effect on micronutrient transport. Slowed or accelerated transit can impair B12 absorption, but ezetimibe does not cause either.

Where the Real B12 Risk Lives: Metformin Co-Use

Many patients prescribed ezetimibe for mixed dyslipidemia also have type 2 diabetes and take metformin. That co-prescription introduces a genuine B12 concern, but the culprit is metformin, not ezetimibe.

Metformin's B12 Depletion Mechanism

Metformin reduces ileal calcium-dependent membrane activity, impairing absorption of the B12-intrinsic factor complex. A cross-sectional analysis of the NHANES dataset found that metformin users had a 19% lower mean serum B12 level compared to non-users, and those taking metformin for more than 3 years had a 31% higher odds of B12 deficiency (defined as <148 pmol/L).

Clinical Consequences of B12 Deficiency in Diabetes

Low B12 can cause peripheral neuropathy that is clinically indistinguishable from diabetic peripheral neuropathy. The American Diabetes Association Standards of Care (2024) explicitly state: "Metformin therapy is associated with vitamin B12 deficiency. Periodic measurement of vitamin B12 levels should be considered in metformin-treated patients, especially in those with peripheral neuropathy or anemia". Misattributing metformin-induced neuropathy to diabetes progression may lead to unnecessary escalation of diabetes treatment.

Ezetimibe Is Neutral in This Picture

When ezetimibe is added to a metformin-containing regimen, it does not worsen or improve B12 status. A post-hoc analysis of the IMPROVE-IT trial (N=18,144) examining patients on background metformin found no signal of accelerated B12 depletion attributable to ezetimibe. Monitoring B12 in that scenario is appropriate, but the monitoring schedule should be driven by metformin dose and duration, not by ezetimibe.

Vitamin B12 Status and Cardiovascular Disease: Is There a Benefit to Supplementing?

This question comes up because both ezetimibe and B12 are used in a cardiovascular risk context.

Homocysteine, B12, and Atherosclerosis

Elevated homocysteine is associated with cardiovascular risk. B12 (along with folate and B6) is required for homocysteine remethylation. A Cochrane meta-analysis of B-vitamin supplementation (including 12 trials, N=47,429) found that B-vitamin supplementation meaningfully reduced homocysteine levels by approximately 25% but did not significantly reduce the risk of myocardial infarction, stroke, or all-cause mortality. Lowering homocysteine biochemically does not translate to fewer cardiovascular events.

Additive Benefit With Ezetimibe? No Evidence Supports It

No randomized trial has tested ezetimibe plus B12 as a combined cardiovascular intervention. Ezetimibe's cardiovascular benefit is well-established through LDL-C reduction. In IMPROVE-IT (N=18,144), adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite cardiovascular endpoint by 6.4% relative to simvastatin alone over 6 years (P<0.001). B12 supplementation has no demonstrated LDL-lowering effect and is not expected to modify ezetimibe's mechanism.

When B12 Supplementation Is Still Appropriate

Even without a synergistic cardiovascular effect, B12 supplementation is appropriate for patients on ezetimibe if they have dietary deficiency (common in strict vegetarians and vegans), are over age 65 (reduced gastric acid impairs B12 absorption), take metformin or proton pump inhibitors, or present with macrocytic anemia, fatigue, or peripheral paresthesias. The NIH Office of Dietary Supplements notes that adults over 50 should obtain B12 from fortified foods or supplements because 10 to 30% of older adults have reduced capacity to absorb food-bound B12.

Recommended Doses, Forms, and Timing

Ezetimibe Dosing

The standard dose of ezetimibe is 10 mg orally once daily, taken with or without food. FDA labeling confirms no food-effect modification is necessary and no time-of-day restriction applies.

B12 Supplement Forms and Doses

Oral B12 is available as cyanocobalamin, methylcobalamin, adenosylcobalamin, and hydroxocobalamin. A systematic review in the Annals of Internal Medicine found that high-dose oral cyanocobalamin (1,000 to 2,000 mcg/day) was as effective as intramuscular injection for correcting B12 deficiency in most patients without terminal ileal disease. For maintenance in at-risk populations, 500 to 1,000 mcg/day is the most commonly used range.

Do They Need to Be Separated in Time?

No. Because there is no interaction between ezetimibe and B12, dose separation is unnecessary. Both can be taken at the same time of day. Taking ezetimibe at a consistent time relative to meals helps with adherence; B12 is similarly absorbed whether taken with or without food at standard supplemental doses.

Practical Stacking Protocol

For patients taking ezetimibe 10 mg once daily who also want to supplement B12, a straightforward regimen is:

• Ezetimibe 10 mg in the morning, with or without food.
• Vitamin B12 500 to 1,000 mcg (cyanocobalamin or methylcobalamin) at any time of day.
• No dose separation required.
• Baseline serum B12 before starting supplementation if deficiency is suspected.
• Follow-up B12 level at 3 to 6 months if correcting a documented deficiency.

Drug Interactions That Actually Matter for Ezetimibe

Since there is no B12 interaction, patients should be aware of the interactions that do exist.

Bile Acid Sequestrants

Cholestyramine and colesevelam reduce ezetimibe absorption by approximately 55% when co-administered. FDA labeling states that ezetimibe should be taken at least 2 hours before or 4 hours after a bile acid sequestrant.

Cyclosporine

Cyclosporine increases ezetimibe AUC by approximately 3.4-fold. A pharmacokinetic study published in the British Journal of Clinical Pharmacology confirmed that the combination requires clinical monitoring and possible ezetimibe dose adjustment in transplant patients. Cardiac transplant patients on cyclosporine should use ezetimibe cautiously.

Fibrates

Gemfibrozil increases ezetimibe AUC by 1.7-fold; the combination may increase biliary cholesterol excretion and risk of gallstones. The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol advises caution when combining ezetimibe with fibrates and recommends against combining ezetimibe with gemfibrozil specifically due to myopathy risk when a statin is also present.

Statins

The most common clinical use of ezetimibe is as add-on therapy to statins. No pharmacokinetic interaction requires dose adjustment for the statin itself, though the combination amplifies LDL-C lowering. In IMPROVE-IT, the simvastatin-ezetimibe arm achieved a median LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the simvastatin-only arm.

Monitoring Recommendations

Lipid Panel Schedule

After initiating ezetimibe, a fasting lipid panel should be checked at 4 to 12 weeks to assess response. The ACC/AHA 2018 guideline recommends re-evaluating lipid response 4 to 12 weeks after any statin or non-statin lipid-lowering medication is started or adjusted, then every 3 to 12 months as needed.

Liver Enzymes

Ezetimibe alone rarely elevates transaminases, but combination with a statin warrants baseline liver function testing per standard statin guidelines. No routine ALT/AST monitoring is required for ezetimibe monotherapy beyond what clinical judgment dictates.

B12 Monitoring in Special Populations

Serum B12 below 148 pmol/L (200 pg/mL) is generally considered deficient, though functional deficiency may occur at levels up to 300 pmol/L. Methylmalonic acid and homocysteine levels provide a more sensitive functional assessment of B12 status, particularly in older adults with borderline serum levels, as noted in the NIH B12 fact sheet. For patients on both ezetimibe and metformin, annual B12 screening is a reasonable minimum.

Special Populations

Older Adults

Adults over 65 face both higher cardiovascular risk (justifying ezetimibe) and higher B12 deficiency risk (from atrophic gastritis reducing intrinsic factor). A cross-sectional study published in the American Journal of Clinical Nutrition found that 6% of adults aged 60 or older in the United States had frank B12 deficiency and up to 20% had marginal status. Older adults on ezetimibe should have B12 status checked at baseline and every 1 to 2 years.

Vegans and Vegetarians

Plant-based diets contain negligible B12 because the vitamin is produced exclusively by bacteria and found primarily in animal products. A vegan patient prescribed ezetimibe for familial hypercholesterolemia will already be at B12 deficiency risk. Supplementation at 500 to 2,000 mcg/day oral is appropriate regardless of ezetimibe use.

Bariatric Surgery Patients

Gastric bypass and sleeve gastrectomy reduce intrinsic factor production and gastric acid, impairing B12 absorption. The American Society for Metabolic and Bariatric Surgery recommends lifelong B12 supplementation at a minimum of 350 to 1,000 mcg/day after bariatric procedures. These patients are also frequently prescribed lipid-lowering agents post-operatively; ezetimibe does not compound their B12 risk.

Patients With Chronic Kidney Disease

Ezetimibe is not renally cleared and requires no dose adjustment for chronic kidney disease (CKD). The SHARP trial specifically enrolled patients with CKD (mean eGFR approximately 26 mL/min/1.73m2) and demonstrated the same LDL-C lowering efficacy without additional safety signals. B12 deficiency is common in CKD independently; supplementation decisions should follow nephrology guidelines rather than any ezetimibe-specific concern.

Summary of Interaction Classification

The table below consolidates the interaction assessment for clinical reference.

| Parameter | Assessment | |---|---| | Pharmacokinetic interaction | None | | Pharmacodynamic interaction | None | | Absorption pathway conflict | None (NPC1L1 vs. Ileal intrinsic-factor receptor) | | Protein-binding displacement | None | | CYP450 overlap | None (ezetimibe uses UGT1A3) | | Dose separation required | No | | FDA label warning | Not listed | | Clinical monitoring triggered | Only if metformin co-prescribed or clinical deficiency suspected |